OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Gilead Sciences (GILD) Announces Acquisition of XinThera
-
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
-
Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Kinnate Biopharma Inc. For: Apr 28 Filed by: ORBIMED ADVISORS LLC
-
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
W&T Offshore (WTI) Appoints Nancy Chang to its Board
-
W&T Announces Addition to Its Board of Directors
-
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
-
Form 4 TELA Bio, Inc. For: Apr 19 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 144 TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 144 Galecto, Inc. Filed by: OrbiMed Advisors Israel II Ltd
-
Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 144 Galecto, Inc. Filed by: OrbiMed Advisors Israel II Ltd
-
Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 144 Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
-
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
-
Form SC 13D/A Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
-
Form SC 13D/A CalciMedica, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A CalciMedica Inc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million
-
Form SC 13D/A Fusion Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 4 Enliven Therapeutics, For: Feb 23 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A VistaGen Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A VectivBio Holding AG Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Theravance Biopharma, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Sonendo, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A SI-BONE, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Protara Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A RxSight, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Jounce Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Harpoon Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Mersana Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Mereo Biopharma Group Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A MeiraGTx Holdings plc Filed by: ORBIMED ADVISORS LLC

